SCHEMBL4444240

SCHEMBL4444240

Cc1ccc(-c2ccc(O)cc2)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.57
ALK Q9UM73 1/20 0.48
ESR1 P03372 4/20 0.46
ESR2 Q92731 3/20 0.46
TDP1 Q9NUW8 1/20 0.43
HSD17B1 P14061 4/20 0.43
HSD17B2 P37059 3/20 0.43
SHBG P04278 1/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.42
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SENP1 Q9P0U3 1/20 0.41
CSNK2A2 P19784 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23197679 0.88 TDP1 (0.56) GSK3BTDP1KDM4ENPC1ALDH1A1
SCHEMBL16436195 0.83 ESR1 (0.56) ESR1ESR2TDP1SHBGKDM4E
SCHEMBL2319851 0.81 TDP1 (0.48) GSK3BTDP1KDM4ENPC1ALDH1A1
SCHEMBL12669250 0.79 TDP1 (0.46) GSK3BTDP1KDM4ENPC1ALDH1A1
SCHEMBL5539598 0.77 GSK3B (0.57) GSK3BTDP1KDM4ENPC1ALDH1A1
SCHEMBL13212958 0.77 TDP1 (0.43) GSK3BTDP1KDM4ENPC1ALDH1A1
SCHEMBL8532336 0.77 HPGD (0.52) TDP1KDM4ENPC1ALDH1A1GAA
SCHEMBL14781240 0.77 KDM4E (0.46) GSK3BTDP1KDM4ENPC1ALDH1A1
SCHEMBL2615713 0.77 ALDH1A1 (0.48) TDP1KDM4ENPC1ALDH1A1GAA
SCHEMBL5541749 0.77 ALDH1A1 (0.65) TDP1KDM4ENPC1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2985282-A1 GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) 2016-02-17 EP disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed
US-20090156635-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS GILLESPIE PAUL 2009-06-18 US disclosed
US-7524870-B2 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators HOFFMANN-LA ROCHE INC. (US) 2009-04-28 US disclosed
CN-101068803-A Biaryloxymethylarene carboxylic acid compounds HOFFMANN LA ROCHE (CH) 2007-11-07 CN disclosed
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GILLESPIE PAUL 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156635-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS GYS2, GYS1, GSK3A GSK3B 4/4885ALK 3443/4885ESR1 1085/4885
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GYS2, GYS1, GSK3A GSK3B 4/4885ALK 3443/4885ESR1 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.